logo
Plus   Neg
Share
Email

Biogen Stops Development Of Gosuranemab For Progressive Supranuclear Palsy

Biogen Inc. (BIIB) said that it will discontinue development of gosuranemab for progressive supranuclear palsy and other primary tauopathies.

The primary endpoint of the Phase 2 PASSPORT of gosuranemab for progressive supranuclear palsy was not statistically significant. In addition, the study did not demonstrate efficacy on key clinical secondary endpoints.

The company noted that it will continue its ongoing Phase 2 TANGO study of gosuranemab for mild cognitive impairment due to Alzheimer's disease (AD) or mild AD, given differences in disease pathology.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration has granted accelerated approval to Tazverik for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Epithelioid sarcoma is a rare sub-type of soft... STIHL recalls about 16,400 STIHL RE 90 pressure washers due to injury hazard. According to the company, the recalled pressure washer nozzle can disconnect from the spray wand when under pressure during use, posing an injury hazard. STIHL said it received seven reports of the nozzle detaching from... CVS Health Corp. launched 13 new HealthHUB locations in CVS Pharmacy stores across Philadelphia and South New Jersey. The healthcare company said it developed the HealthHUB store format to help people manage chronic conditions more conveniently and affordably. The store also features health and wellness products, clinical services and expertise.
Follow RTT
>